Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients.

Sanai N, Li J, Boerner J, Stark K, Wu J, Kim S, Derogatis A, Mehta S, Dhruv HD, Heilbrun LK, Berens ME, LoRusso PM.

Clin Cancer Res. 2018 Aug 15;24(16):3820-3828. doi: 10.1158/1078-0432.CCR-17-3348. Epub 2018 May 24.

2.

Evaluation of pre-analytical factors affecting plasma DNA analysis.

Markus H, Contente-Cuomo T, Farooq M, Liang WS, Borad MJ, Sivakumar S, Gollins S, Tran NL, Dhruv HD, Berens ME, Bryce A, Sekulic A, Ribas A, Trent JM, LoRusso PM, Murtaza M.

Sci Rep. 2018 May 9;8(1):7375. doi: 10.1038/s41598-018-25810-0.

3.

EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.

Roos A, Dhruv HD, Peng S, Inge LJ, Tuncali S, Pineda M, Millard N, Mayo Z, Eschbacher JM, Loftus JC, Winkles JA, Tran NL.

Mol Cancer Res. 2018 Jul;16(7):1185-1195. doi: 10.1158/1541-7786.MCR-18-0125. Epub 2018 May 3.

4.

When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM.

Bollam SR, Berens ME, Dhruv HD.

Curr Neurol Neurosci Rep. 2018 Mar 10;18(4):15. doi: 10.1007/s11910-018-0825-7. Review.

PMID:
29525892
5.

Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition.

Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, Galeas J, Dhruv HD, Berens ME, Schreiber SL, McCormick F, McManus MT.

Nature. 2017 Nov 9;551(7679):247-250. doi: 10.1038/nature24297. Epub 2017 Nov 1.

6.

Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation.

Bell JB, Eckerdt F, Dhruv HD, Finlay D, Peng S, Kim S, Kroczynska B, Beauchamp EM, Alley K, Clymer J, Goldman S, Cheng SY, James CD, Nakano I, Horbinski C, Mazar AP, Vuori K, Kumthekar P, Raizer J, Berens ME, Platanias LC.

Mol Cancer Res. 2018 Jan;16(1):32-46. doi: 10.1158/1541-7786.MCR-17-0397. Epub 2017 Oct 17.

7.

Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway.

Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada K, Aguirre AJ, Viswanathan SR, Chattopadhyay S, Tamayo P, Yang WS, Rees MG, Chen S, Boskovic ZV, Javaid S, Huang C, Wu X, Tseng YY, Roider EM, Gao D, Cleary JM, Wolpin BM, Mesirov JP, Haber DA, Engelman JA, Boehm JS, Kotz JD, Hon CS, Chen Y, Hahn WC, Levesque MP, Doench JG, Berens ME, Shamji AF, Clemons PA, Stockwell BR, Schreiber SL.

Nature. 2017 Jul 27;547(7664):453-457. doi: 10.1038/nature23007. Epub 2017 Jul 5.

8.

Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma.

Vitucci M, Irvin DM, McNeill RS, Schmid RS, Simon JM, Dhruv HD, Siegel MB, Werneke AM, Bash RE, Kim S, Berens ME, Miller CR.

Neuro Oncol. 2017 Sep 1;19(9):1237-1247. doi: 10.1093/neuonc/nox050.

9.

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.

McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AED, Hadler MJ, Sulman EP, Sarkaria JN, Anders CK, Graves LM, Berens ME, Johnson GL, Miller CR.

Neuro Oncol. 2017 Oct 19;19(11):1469-1480. doi: 10.1093/neuonc/nox044.

10.

Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.

Roos A, Dhruv HD, Mathews IT, Inge LJ, Tuncali S, Hartman LK, Chow D, Millard N, Yin HH, Kloss J, Loftus JC, Winkles JA, Berens ME, Tran NL.

Oncotarget. 2017 Feb 14;8(7):12234-12246. doi: 10.18632/oncotarget.14685.

11.

SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide.

Ensign SP, Roos A, Mathews IT, Dhruv HD, Tuncali S, Sarkaria JN, Symons MH, Loftus JC, Berens ME, Tran NL.

Mol Cancer Res. 2016 Mar;14(3):302-12. doi: 10.1158/1541-7786.MCR-15-0183. Epub 2016 Jan 13.

12.

Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway.

Dhruv HD, Roos A, Tomboc PJ, Tuncali S, Chavez A, Mathews I, Berens ME, Loftus JC, Tran NL.

J Neurooncol. 2016 Feb;126(3):397-404. doi: 10.1007/s11060-015-1981-0. Epub 2015 Nov 12.

13.

Intravenous delivery of camptothecin-loaded PLGA nanoparticles for the treatment of intracranial glioma.

Householder KT, DiPerna DM, Chung EP, Wohlleb GM, Dhruv HD, Berens ME, Sirianni RW.

Int J Pharm. 2015 Feb 20;479(2):374-80. doi: 10.1016/j.ijpharm.2015.01.002. Epub 2015 Jan 3.

14.

FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion.

Whitsett TG, Fortin Ensign SP, Dhruv HD, Inge LJ, Kurywchak P, Wolf KK, LoBello J, Kingsley CB, Allen JW, Weiss GJ, Tran NL.

Clin Exp Metastasis. 2014 Aug;31(6):613-23. doi: 10.1007/s10585-014-9653-6. Epub 2014 Apr 8.

PMID:
24710956
15.

Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioblastoma cell chemotaxis via Lyn activation.

Dhruv HD, Whitsett TG, Jameson NM, Patel F, Winkles JA, Berens ME, Tran NL.

Carcinogenesis. 2014 Jan;35(1):218-26. doi: 10.1093/carcin/bgt289. Epub 2013 Aug 23.

16.

Reciprocal activation of transcription factors underlies the dichotomy between proliferation and invasion of glioma cells.

Dhruv HD, McDonough Winslow WS, Armstrong B, Tuncali S, Eschbacher J, Kislin K, Loftus JC, Tran NL, Berens ME.

PLoS One. 2013 Aug 15;8(8):e72134. doi: 10.1371/journal.pone.0072134. eCollection 2013.

17.

Molecular determinants of lung cancer metastasis to the central nervous system.

Whitsett TG, Inge LJ, Dhruv HD, Cheung PY, Weiss GJ, Bremner RM, Winkles JA, Tran NL.

Transl Lung Cancer Res. 2013 Aug;2(4):273-83. doi: 10.3978/j.issn.2218-6751.2013.03.12. Review.

18.

Bioresponsive copolymers of poly(N-isopropylacrylamide) with enzyme-dependent lower critical solution temperatures.

Overstreet DJ, Dhruv HD, Vernon BL.

Biomacromolecules. 2010 May 10;11(5):1154-9. doi: 10.1021/bm100035f.

PMID:
20380371

Supplemental Content

Loading ...
Support Center